Drug intelligence / Profile preview

PTG-200

Development stage: Discontinued
Lead developer: Janssen Biotech
Modality: Peptides, Small Molecules
Administration: Oral

Overview

PTG-200 (JNJ-67864238) is a first-in-class, oral peptide drug that acts as a selective antagonist of the interleukin-23 receptor (IL-23R). It is designed to block IL-23 signaling locally in intestinal tissues by binding to the IL-23 receptor. The drug was developed for gastrointestinal-restricted action with minimal systemic exposure. Its primary indication was for the treatment of moderate to severe Crohn's disease. PTG-200 was co-developed by Protagonist Therapeutics and Janssen Biotech[1][3][7][8].

Targets

IL23R (Interleukin-23 Receptor)

Beyond the preview

Go deeper on PTG-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTG-200.

Explore the full profile